Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental antibody VRC01 tested in early HIV – safety first

NCT ID NCT02591420

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This early-stage study tested whether an experimental antibody called VRC01 is safe and can lower the amount of HIV in the blood of 24 adults who were recently infected. Some participants received VRC01 alone, while others received it together with standard HIV medications. The main goal was to check for side effects and see how the virus levels changed over a week. This is not a cure, but a step toward better control of HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

  • ECHO Center Non-Network CRS

    Chon Buri, Thailand

  • Kenya Med. Research Inst./Walter Reed Project, Clinical Research Centre, Off Hospital Road. Kericho

    Kericho, 20200, Kenya

  • Makerere University Walter Reed Project (MUWRP)

    Kampala, Uganda

  • National Institute for Medical Research (NIMR)-Mbeya Medical Research Center (MMRC) Non-Network CRS

    Mbeya, Tanzania

  • SEARCH Thai Red Cross AIDS Research Centre Non-Network CRS

    Bangkok, 10330, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.